Incyte Biosciences International

Incyte is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics in oncology, inflammation, and autoimmunity. Headquartered in Wilmington, Delaware, with international operations based in Morges, Switzerland, the company is a leader in the development of Janus kinase (JAK) inhibitors. Its commercial portfolio includes Jakafi for myeloproliferative neoplasms and Opzelura, the first topical JAK inhibitor approved for atopic dermatitis and vitiligo. Incyte maintains a robust clinical pipeline featuring small molecules and monoclonal antibodies targeting diverse pathways such as FGFR, PD-1, and PI3K delta. The company leverages strategic global partnerships to maximize the reach of its innovative treatments across North America, Europe, and Asia.